Coronary/Structural Heart

FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation

SILVER SPRING, Md., March 14, 2019 /PRNewswire/ — The U.S. Food and Drug Administration today approved a new indication for a heart valve repair device that is intended to reduce moderate-to-severe or severe mitral regurgitation, a leakage of blood backward through the mitral valve into the heart’s left atrium that can cause […]

ABBOTT RECEIVES FDA APPROVAL FOR EXPANDED INDICATION FOR MITRACLIP™ DEVICE

ABBOTT PARK, Ill., March 14, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip™ device used to repair a leaky mitral valve without open-heart surgery. Supported by the results of the landmark COAPT™ Trial, […]

eMurmur Announces Launch of Its eMurmur Heartpedia App

OTTAWA, Ontario–(BUSINESS WIRE)–eMurmur today announced the release of eMurmur Heartpedia, an app designed to help patients, parents and medical professionals better understand heart defects through anatomically-correct 3D models and corresponding heart and murmur sound recordings for each defect. eMurmur Heartpedia is a major upgrade to the original Heartpedia app from […]

Level Ex® Turns the Practice of Cardiology into a Video Game with Launch of Cardio ExTM

CHICAGO–(BUSINESS WIRE)–Level Ex, creators of industry-leading medical video games for physicians, today announced its expansion into cardiology with the launch of Cardio Ex. Their fourth specialty game, available free in the App Store, presents interventional cardiologists with adrenaline-pumping scenarios that push their cognitive, spatial-reasoning, and decision-making skills to the limits—preparing […]

Conavi Medical Announces Health Canada Approval of Novasight Hybrid System for Visualization During Coronary Angioplasty Procedures

TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com) is pleased to announce that it has received a Health Canada Medical Device License for the Novasight HybridTM System. This patented technology is the only clinical system that enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT), and was […]

Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine

ANN ARBOR, Mich., March 13, 2019 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) announced that results from the 2,230 patient, 52-week, Phase 3 long-term safety study of bempedoic acid (CLEAR Harmony, also known as Study 1 or 1002-040) were published today in The New England Journal of Medicine (NEJM). Bempedoic acid is being […]

Bay Labs’ New Studies at ACC.19 Demo Accuracy, Efficiency and Reproducibility of its AI Software

SAN FRANCISCO – March 13, 2019 – Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, today announced the presentation of two studies assessing performance of the company’s deep learning software. The first evaluated the company’s software when used by medical professionals […]

Bay Labs Announces New Data that Evaluates Accuracy, Efficiency and Reproducibility of EchoGPS™ and AutoEF AI Software

Bay Labs Announces New Data that Evaluates Accuracy, Efficiency and Reproducibility of EchoGPS™ and AutoEF AI Software Results Presented at the American College of Cardiology ACC.19 68th Annual Scientific Session  SAN FRANCISCO – March 13, 2019 – Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) […]

Itamar Medical to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019

CAESAREA, Israel, March 12, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that Gilad Glick, Chief Executive Officer of Itamar Medical, will […]

AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019

WILMINGTON, Del.–(BUSINESS WIRE)–Data evaluating the cardiovascular (CV) effects of FARXIGA® (dapagliflozin),including hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session on March 16-18. The data are the […]